Constipation Pipeline Insight, 2025: Key Players Shaping the Future, including AbbVie, AstraZeneca, and Bausch Health | DelveInsight

The treatment landscape for constipation, a prevalent gastrointestinal disorder, is undergoing significant advancements as new therapies aim to address the limitations of traditional treatments. As awareness grows about the various underlying causes of constipation, including chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome (IBS)-related constipation, novel therapeutic strategies are emerging. These include targeted therapies, bioactive agents, and minimally invasive treatments that promise enhanced patient outcomes and improved quality of life.

DelveInsight's "Constipation - Pipeline Insight, 2025" provides a detailed analysis of ongoing clinical and preclinical research, showcasing innovative drug candidates, biological therapies, and alternative treatment strategies. From prokinetic agents and stool softeners to neuromodulators and microbiome-based therapies, the constipation pipeline is rapidly evolving, reflecting a broad, multidisciplinary approach to combating the condition.

This report offers a comprehensive overview of investigational therapies across all stages of development, focusing on administration routes, delivery mechanisms, and regional trial trends. It also highlights key unmet needs, regulatory designations (e.g., fast track, orphan drug status), and the emerging science behind new therapies that have the potential to redefine the treatment of constipation in the coming years.

Interested in learning more about the current treatment landscape and the key drivers shaping the constipation pipeline? Click here: https://www.delveinsight.com/report-store/constipation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Constipation Pipeline Report
• DelveInsight's constipation pipeline analysis depicts a strong space with 15+ active players working to develop 15+ pipeline drugs for constipation treatment.
• The leading constipation companies include Anji Pharma, Yuhan, Theravance Biopharma, RaQualia Pharma, Processa Pharmaceuticals, Abbott, AbbVie, Albireo Pharma, AstraZeneca, Bausch Health Companies, Bayer AG, Cosmo Pharma, and others are evaluating their lead assets to improve the constipation treatment landscape.
• Key constipation pipeline therapies in various stages of development include RQ 00433412, Pradigastat, YH 12852, RQ 00000010, Limosilactobacillus reuteri, SVT 1B149, VS013, and others.
• In December 2024, NeurAxis, Inc. announced that the FDA granted 510(k) clearance for its Rectal Expulsion Device (RED), enabling the company to commercially market the device for testing and evaluating patients with chronic constipation due to pelvic floor dyssynergia who are unlikely to improve with increased laxative use.

Request a sample and discover the recent breakthroughs happening in the constipation pipeline landscape @ https://www.delveinsight.com/report-store/constipation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Constipation Overview
Constipation is characterized by having fewer than three bowel movements a week, hard or dry stools, difficulty or pain during passage, or the sensation of incomplete bowel evacuation. It often results from sluggish stool movement in the colon, which can be caused by medications, organic conditions, pelvic floor dysfunction, or diet. Serious causes include a distended abdomen, vomiting, blood in the stool, weight loss, and worsening symptoms in older adults. Chronic constipation with abdominal discomfort and long-term laxative use suggests slow-transit constipation, while sudden onset in conjunction with new medications may point to drug-induced constipation.

New or worsening constipation in the absence of known causes may indicate a colonic tumor or partial obstruction. Excessive straining or difficulty defecating may signal a defecatory disorder. Chronic constipation without a clear cause may be classified as functional constipation. Diagnosis may require colonoscopy, lab tests, and imaging studies to rule out underlying conditions. Constipation is more common in older adults due to factors like low fiber intake, inactivity, medical conditions, and medication use.

Find out more about constipation medication @ https://www.delveinsight.com/report-store/constipation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Constipation Treatment Analysis: Drug Profile
Pradigastat (ANJ908): Anji Pharma
ANJ908 (Pradigastat) shows great promise for treating chronic idiopathic constipation (CIC) and irritable bowel syndrome-associated constipation (IBS-C), two common conditions with limited effective treatments. By inhibiting DGAT1, ANJ908 enhances fatty acid levels in the gut, increasing colon motility and water secretion, both crucial for effective constipation treatment. Anji Pharma has initiated a Phase 2 trial to evaluate ANJ908 in patients with functional constipation.

YH12852: Yuhan
YH12852 is a potent and selective 5-hydroxytryptamine receptor agonist that has demonstrated the ability to improve gastrointestinal motility in both healthy volunteers and patients with functional constipation. The drug is currently in a Phase 1/2a trial involving healthy subjects and patients with functional constipation.

RQ-00000010: RaQualia Pharma
RQ-00000010 is a selective 5HT4 partial agonist that stimulates gastrointestinal motility. After completing Phase 1 clinical trials, the compound has shown superior safety, tolerability, and pharmacokinetic profiles, along with effective gastric emptying acceleration. It holds promise as a treatment for functional gastrointestinal disorders like gastroparesis and functional dyspepsia, as well as for chronic constipation.

Learn more about the novel and emerging constipation pipeline therapies @ https://www.delveinsight.com/report-store/constipation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Constipation Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Constipation Pipeline Report
• Coverage: Global
• Key Constipation Companies: Anji Pharma, Yuhan, Theravance Biopharma, RaQualia Pharma, Processa Pharmaceuticals, Abbott, AbbVie, Albireo Pharma, AstraZeneca, Bausch Health Companies, Bayer AG, Cosmo Pharma, and others.
• Key Constipation Pipeline Therapies: RQ 00433412, Pradigastat, YH 12852, RQ 00000010, Limosilactobacillus reuteri, SVT 1B149, VS013, and others.

Dive deep into rich insights for drugs used for constipation treatment; visit @ https://www.delveinsight.com/report-store/constipation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Constipation Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Constipation Pipeline Therapeutics
6. Constipation Pipeline: Late-Stage Products (Phase III)
7. Constipation Pipeline: Mid-Stage Products (Phase II)
8. Constipation Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading market research and business consulting firm specializing in the life sciences industry. We provide pharmaceutical companies with tailored, end-to-end solutions to optimize their strategies and enhance business outcomes. With our subscription-based platform, PharmDelve, you can access a comprehensive range of healthcare and pharma market research reports, ensuring informed decision-making and sustained growth.

This release was published on openPR.